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Abstract
Introduction: Down syndrome (DS), a major cause of mental retardation, is caused by trisomy of some or all of
human chromosome 21 and includes three basic karyotypes: trisomy 21, translocation, and mosaicism. The
derivation of DS-specific induced pluripotent stem cells (iPSCs) provides us novel DS models that can be used to
determine the DS mechanism and to devise therapeutic approaches for DS patients.
Methods: In the present study, fibroblasts from patients with DS of various karyotypes were reprogrammed into
iPSCs via the overexpression of four factors: OCT4, SOX2, KLF4, and c-MYC, by using lentiviral vectors. The abilities
of the iPSC-DS in the self-renewal and pluripotency in vitro and in vivo were then examined.
Results: The iPSC-DS showed characteristics similar to those of human embryonic stem cells, particularly the
morphology, surface marker (SSEA4, TRA-1-60, and TRA-1-81) expression, pluripotent-specific transcription-factor
expression levels, and methylation status of the OCT4 promoter. The pluripotency of iPSC-DS was also tested in
vitro and in vivo. Embryoid bodies were formed and showed the expression of differentiated markers for three
germ layers. Furthermore, iPSC-DS formed classic teratomas when injected into nonobese diabetic-severe
combined immunodeficient (NOD-SCID) mice.
Conclusions: iPSCs were generated from patients with DS. The iPSCs derived from different types of DS may be
used in DS modeling, patient-care optimization, drug discovery, and eventually, autologous cell-replacement
therapies.
Introduction
Down syndrome (DS) is the major cause of congenital
heart disease and the most frequent genetic cause of
mental retardation, which occurs in roughly one of 700
live births [1]. In addition to the characteristic dysmor-
phology of the facial and physical features, DS is asso-
ciated with increased risks of leukemia, immune system
defects, and an early Alzheimer-like dementia [2]. DS
includes caused by the presence of an extra chromo-
some 21 (trisomy 21), subsets of the phenotypic features
of DS may be caused by the duplication of parts of the
chromosome 21(translocation) [2,3]. Although transloca-
tion affects only about four of 100 people with DS, it is
also associated with a number of deleterious phenotypes.
Mosaicism results from the abnormal cell division in
some cells after fertilization, with some of the cells hav-
ing 47 chromosomes, and the others being normal [4,5].
Understanding and investigating the mechanisms of DS
present a considerable challenge because of the genetic
complexity and individual variability of the DS
phenotypes.
An important approach to the genetic analysis of DS
is the establishment and study of analogous mouse
models. Although several types of DS mouse models,
such as Ts65Dn [6,7] and Ts1Cje [8,9], are useful, the
mouse model should have a phenotype that can be
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reasonably related to the human condition. Human
embryonic stem cells (hESCs) have proven to be another
source for the modeling of genetic diseases [10]; how-
ever, the establishment of hESCs with DS is limited by
ethical dilemmas. In addition, the transplantation of
hESCs-differentiated cells can trigger an immune rejec-
tion by the host. Induced pluripotent stem cells (iPSCs)
possess the properties of hESCs, such as self-renewal
and pluripotent potentials, but are superior to hESCs in
the generation of disease-specific and patient-specific
iPSCs without any accompanying controversy [11-14].
Recent studies showed that a variety of disease-specific
iPSCs may be successfully produced [15-22]. Even in
mouse and rat models, disease phenotypes were signifi-
cantly ameliorated by gene-corrected, iPSC-differen-
tiated cells [23-25]; these results provide the theoretic
basis for iPSC-based therapies.
In the current study, iPSCs were generated from DS
patients with different karyotypes (trisomy 21 and trans-
location) via the overexpression of four factors: OCT4,
SOX2, KLF4, and c-MYC. The generated DS-specific
iPSCs can be effective cell models for the study of the
DS mechanism as well as for drug screening. Further-




All animal experimental procedures and protocols were
approved by the Ethics Committee of Fu Wai Hospital
and were in accordance with the Guide for the Care and
Use of Laboratory Animals (approval number: 0000284).
Written approvals for human skin-tissue collection, sub-
sequent iPSC generation, and genome/gene analyses
performed in the current study were obtained from the
Ethics Committee for Human Research at Fu Wai Hos-
pital (approval number: 241). Two patients are involved
in the study. Patient 1 was presented at age 3 years with
translocation (DS/Translocation). Patient 2 was pre-
sented at age 4 years with trisomy 21 (DS/Trisomy 21).
Written informed consent was obtained from the guar-
dian of each participant.
Cell culture
Human dermal fibroblasts (HDFs) were derived from
the skin via operative incision when the patients under-
went cardiac surgery. The HDFs were maintained in
Dulbecco modified Eagle medium (DMEM) containing
10% fetal bovine serum (FBS), 1% nonessential amino
acids, 0.1% b-mercaptoethanol, and 1% penicillin/strep-
tomycin. The iPSCs and hESC-H7 (WiCell Research
Institute, Madison, Wisconsin, USA) were maintained
on a protein gelatin (Matrigel; BD) with irradiated
mouse embryonic fibroblast-conditioned medium (MEF-
CM) in DMEM/F12 supplemented with 20% KnockOut
Serum Replacement (Invitrogen), 1% nonessential amino
acids, 1 mM L-glutamine, 0.1% b-mercaptoethanol, and
4 ng/ml basic fibroblast growth factor (bFGF).
Lentivirus production
The 293T (ATCC) cells were seeded overnight at 2 ×
106 to 2.5 × 106 cells per 100-mm dish with DMEM
supplemented with 10% FBS. The cells were co-trans-
fected with pDM2.G and pSPAX2, along with pLM-
vexGFP-OCT4, pLM-mCitrine-SOX2, pLM-mCherry-
KLF4, or pLM-mCerulean-c-MYC (Addgene) with cal-
cium phosphate cell transfection, as previously described
[26]. Around 48 hours after transfection, the medium
containing the lentivirus was collected, and the cellular
debris was removed with centrifugation. The supernate
was filtered through a 0.45-μm filter, and the lentivirus
was pelleted with ultracentrifugation at 33,000 rpm in
45 Ti rotors (Beckman) for 90 minutes at 4°C. The len-
tivirus particles were resuspended in the medium and
stored at -80°C.
Generation of DS-specific iPSCs
For the reprogramming experiments, the HDFs were
infected with a cocktail of lentiviruses expressing exo-
genous OCT4, SOX2, KLF4, and c-MYC in the presence
of 6 μg/ml of polybrene [27]. After 24 hours, the med-
ium was replaced with MEF-CM supplemented with 1
mM valproic acid, which lasted for 2 weeks [28]. The
medium was changed every other day. On day 30,
hESC-like colonies were picked up based on the mor-
phology and plated onto Matrigel-coated wells in MEF-
CM.
Alkaline phosphatase staining and immunostaining
Alkaline phosphatase (AP) staining was performed by
using the Alkaline Phosphatase Detection Kit (Millipore)
according to the manufacturer’s instructions. For the
immunostaining, the fixed cells were incubated with the
primary antibodies of OCT4 (1:100; Chemicon), SSEA4
(1:100; Chemicon), TRA-1-60 (1:100; Chemicon), TRA-
1-81 (1:100; Chemicon), beta-Tubulin III (Tuj1) (1:500;
Sigma), AFP (1:100; Santa Cruz), and cTnT (1:200;
R&D). The secondary antibodies used were cyanine 2
(Cy2)-conjugated rabbit anti-mouse IgM (1:50; Jackson
ImmunoResearch) and rhodamine-conjugated AffiniPure
goat anti-mouse IgG (1:200; Santa Cruz). The nuclei
were stained with 4’,6-diamidino-2-phenylindole (DAPI,
Sigma).
Differentiation in vitro
For the embryoid body (EB) formation, iPSCs and
hESCs were harvested with treatment with dispase. Cell
clumps were cultured in a suspension in ultra-low-
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attachment plates containing the EB differentiation med-
ium (DMEM supplemented with 20% FBS, 1% nones-
sential amino acids, and 1% penicillin/streptomycin).
After 8 days as a floating culture, the EBs were trans-
ferred to a gelatin-coated plate and cultured in the same
medium for another 8 days.
Teratoma formation
For the teratoma formation, 5 × 106 cells of each iPSC
line were harvested and subcutaneously injected into
nonobese diabetic-severe combined immunodeficient
(NOD-SCID) mice with the Matrigel [29]. Eight weeks
after injection, the teratomas were dissected and fixed
with PBS containing 4% paraformaldehyde. The paraf-
fin-embedded tissues were sectioned and stained with
hematoxylin and eosin (HE staining).
Semiquantitative and quantitative reverse-transcription
polymerase chain reaction (RT-PCR)
Total RNA was extracted from the cells by using TRIzol
(Invitrogen) and was transcribed into cDNA by using a
HiFi-MMLV cDNA kit (CWBIO). Semiquantitative RT-
PCR was subsequently performed to detect the expression
of total and endogenous pluripotency-associated genes, as
well as the genes representing the three germ layers.
Quantitative RT-PCR was performed by using a RealSuper
Mixture (with Rox) to indicate the total expression level of
the four pluripotency-associated genes. The transcript
levels were determined by using the 7500 Real-Time PCR
System (Applied Biosystems). The gene expression was
normalized to b-actin (ACTB) as the internal standard.
The primers are provided in Supplementary Table 2.
Bisulfite sequencing
Genomic DNA was purified and treated with a CpGe-
nome DNA Modification Kit (Chemicon) according to
the manufacturer’s recommendations. The treated DNA
was subjected to nested PCR to obtain the promoter
regions of human OCT4. The primer information is
provided in Supplementary Table 2. The PCR products
were cloned into pGEM-T Easy plasmids and trans-
formed into TOP10 cells. Ten clones of each sample
were sequenced.
Karyotype analysis and short tandem repeat analysis
Karyotype analysis was conducted by using standard
protocols for the chromosomal Giemsa (G)-banding at
the Peking University Health Science Center. Short tan-
dem repeat analysis was performed at the Center of For-
ensic Sciences, Beijing Genomics Institute.
Statistical analysis
The results are reported as the mean ± SEM. The statis-
tical significance of the differences was determined by a
one-way ANOVA. Values with P < 0.05 were considered
statistically significant.
Results
Reprogramming of HDFs from patients with DS into iPSCs
To generate iPSC-DS, HDF-DS were obtained from skin
biopsies obtained from the boys with congenital heart
disease when the patients underwent cardiac surgery.
The lentiviruses containing OCT4, SOX2, KLF4, and c-
MYC were introduced into HDFs [30], and the cells
were plated onto Matrigel-coated plates. On the day
after transduction, MEF-CM was applied to the Matri-
gel-coated plates with 1 mM valproic acid, which lasted
for 2 weeks [28]. Approximately 7 days after transduc-
tion, small cell clumps clearly distinguishable from the
fibroblasts started to grow. At around 20 days, some
hESC-like colonies with morphologies resembling those
of hESCs with a high nuclear-to-cytoplasmic ratio began
to form. The colonies were picked out and propagated
in MEF-CM on Matrigel. After several passage expan-
sions, several iPSC lines were selected for further analy-
sis (Figure 1).
Expression of pluripotent-specific markers by human
iPSC-DS lines and silencing of the lentivirally delivered
transgene
To characterize the generated iPSC-DSs, their expres-
sion of the pluripotent markers was examined by using
alkaline phosphatase (AP) staining and immunostaining.
The reprogrammed cells were positive for AP activity
and expressed the pluripotent-specific surface antigens
SSEA4, TRA-1-60, and TRA-1-81, and the nuclear tran-
scription factor OCT4 (Figure 2). Moreover, quantitative
RT-PCR results show the total expression of the pluri-
potency-associated genes, including OCT4, SOX2, KLF4,
and c-MYC (Figure 3A). The expression of OCT4,
SOX2, KLF4, and c-MYC in the iPSC lines was similar
to that of the hESCs. In addition, the endogenous
expression of OCT4, SOX2, KLF4, and c-MYC was ana-
lyzed with semiquantitative RT-PCR (Figure 3B). The
expression of the endogenous OCT4 and SOX2 was con-
sistently upregulated relative to the parental fibroblasts,
and KLF4 and c-MYC were expressed in iPSCs and
hESCs, as well as in the fibroblasts. As previously
described [30], a pronounced lentiviral vector silencing
is a characteristic of successfully reprogrammed iPSC
clones. In the present study, the lentiviral vectors encod-
ing the four reprogramming factors co-expressed with
discernable fluorescent proteins were used to generate
the iPSCs-DS. Monitoring the expression of each fluor-
escent protein is determined to reveal the expression of
individual reprogramming factor. The expression of four
fluorescent proteins that represent the transgenic
expression was predominantly silenced in all of the
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iPSC-DS lines (data not shown). The results demon-
strate the successfully reprogrammed iPSC-DS.
Activation of the promoters of hESC-specific genes in
human iPSCs
The DNA-methylation status of genomic DNA from
iPSC-DS, parental HDFs, and H7 hESCs were analyzed to
assess the epigenetic reprogramming of iPSC-DS [31].
Among the four transcription factors, OCT4 plays a key
role in maintaining and regaining stem cell pluripotency
[32], and the promoter regions of OCT4 were subjected to
bisulfite genomic sequencing. The results demonstrate the
demethylation status of cytosine guanine dinucleotides
(CpG) in the promoter region of OCT4 for the iPSCs and
their parental fibroblasts (Figure 4). The OCT4 promoter
was released and activated in the reprogrammed iPSC-
DSs, compared with that in the parental fibroblasts, and
was found to be similar to that of hESCs. These results are
consistent with the occurrence of epigenetic remodeling
during reprogramming through gene transduction [11,12].
Embryoid body-mediated differentiation of iPSC-DS in vitro
To evaluate the differentiation ability of iPSC-DS in
vitro, EBs were formed in suspension cultivation. After 8
Figure 1 The reprogramming cells show a similar morphology to hESCs. (A) One induced pluripotent stem cell (iPSC) line derived from a
Down syndrome (DS) patient with translocation (DS/translocation). Morphology of the parental human dermal fibroblasts (HDFs; left), iPSC1
(colony no.1 reprogrammed from HDFs-DS/translocation) before picking the colony (middle), and at passage 8 (right). (B) Two iPSC lines derived
from a DS patient with trisomy 21 (DS/trisomy 21). Morphology of the parental HDFs (left), iPSCs 2 (Colony No. 2 reprogrammed from HDFs-DS/
trisomy 21) and iPSC4 (Colony No. 4 reprogrammed from HDFs-DS/trisomy 21) before picking the colonies (middle), and at passage 5 (right).
Scale bars, 100 μm.
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days in a suspension culture, the EBs were transferred
onto the gelatin-coated plates, and the cultivation was
continued for another 8 days. The attached cells were
then collected for semiquantitative RT-PCR to detect
the expression of GATA4 (endoderm), AFP (endoderm),
RUNX1 (mesoderm), NESTIN (ectoderm), and NCAM
Figure 2 Human induced pluripotent stem cells (iPSCs-DSs) lines express pluripotency markers. The iPSCs expressed alkaline phosphatase.
As shown by the immunostaining results, the cells expressed pluripotency markers, including OCT4, SSEA4, TRA-1-60, and TRA-1-81. (A) DS/
translocation-iPSC1. (B) DS/trisomy 21-iPSC2. (C) DS/trisomy 21-iPSC4. Nuclei are stained with DAPI (blue). Scale bars, 100 μm.
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(ectoderm). Figure 5A shows that iPSC-DS cells possess
the ability to differentiate into cell types originating
from all three germ layers in vitro. Also, immunostain-
ing analyses of lineage markers represent the three germ
layers (Figure 5B).
Teratoma formation from human iPSCs
Ultimately, the fully reprogrammed cells should be able
to form teratomas containing tissue cell types of all
three germ layers in vivo to be truly considered hESC-
like iPSCs. The iPSC-DS cells were injected into NOD-
SCID mice to observe the teratoma formation. Eight
weeks after injection, the teratomas were harvested for
HE staining. The teratomas contained derivatives of the
endoderm (glandular structures), mesoderm (cartilage),
and ectoderm (pigmented epithelium and melanocytes)
(Figure 5C). These results suggest that iPSC-DS can
spontaneously differentiate into derivatives of all three
germ layers in vivo.
Human iPSC-DS derived from HDF-DS, not from a
contamination of laboratory hESCs
Short tandem repeat analysis was conducted to confirm
the origin of the human iPSC-DS. The patterns of 18
short tandem repeats between iPSCs and parental HDFs
completely matched (Supplementary Table 1). These
patterns differed from those of the hESCs cultured in
our laboratory. Karyotype analysis confirms that each
iPSC line generated from the parental fibroblasts main-
tained the normal euploid karyotype after reprogram-
ming (Figure 6).
Discussion
DS is caused by the trisomy of part or all of human
chromosome 21, but its phenotypic features differ from
person to person. Understanding and investigating the
DS mechanisms are challenges because of the genetic
complexity and individual variability of DS phenotypes.
Mouse models are useful for DS research, but DS mod-
eling in mice is particularly complex because of the size
of the region involved as well as the number of candi-
date genes and incomplete synteny between animal and
human chromosomes. The hESCs [33], which have the
potential to provide an unlimited supply of different cell
types for tissue replacement, drug screening, and func-
tional genomics applications, were first derived by
Thomson et al. [34]. Although some hESCs with tris-
omy 21 have been established, the production of differ-
ent types for DS studies is also limited because of
ethical challenges. In addition, the transplantation of
hESC-differentiated cells can trigger immune-rejection
by the host. In the present study, reprogramming iPSC-
Figure 3 The induced pluripotent stem cells (iPSCs-DSs) express pluripotency-associated genes. (A) The total gene-expression levels of
OCT4, SOX2, KLF4, and c-MYC were determined by using quantitative reverse transcription polymerase chain reaction (RT-PCR) in iPSCs-DS and
hESCs. The differences in the expression levels of H7 hESCs and iPSCs-DS were not significant. The results are reported as mean ± SEM (n = 3).
(B) The endogenous (Endo) and total (Total) expression levels of OCT4, SOX2, KLF4, and c-MYC were analyzed with semiquantitative RT-PCR and
compared with parental human dermal fibroblasts. b-Actin (ACTB) was used as the positive control.
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DS could provide a source for DS modeling, optimal
patient care, drug screening, and eventually autologous
cell-replacement therapies. Compared with a previous
study by Park et al. [15], we generated iPSCs from DS
patients with various karyotypes (trisomy 21 and trans-
location). We did not find significant differences
between iPSC-DS/trisomy 21 and iPSC-DS/translocation
cell lines in the abilities of self-renewal and pluripo-
tency. Although our results were consistent with the
previous report, the current study confirmed that iPSCs
can be generated from patients with various karyotypes.
iPSCs were first derived by Yamnaka et al. [11] from
mouse fibroblasts with retroviral vectors. In our study,
we used lentiviral vectors encoding the four transcrip-
tion factors (OCT4, SOX2, KLF4, and c-MYC) co-
expressed with discernable fluorescent proteins to gen-
erate the iPSC-DS. An obvious difference between retro-
viral and lentiviral vectors is the degree of silencing to
which they are subject in pluripotent cells [35]. We have
determined the silencing of exogenous genes by
monitoring expression of each fluorescent protein. It is
know that integration of retroviral and lentiviral vectors
into the genome may affect the behaviors of the iPSCs,
for sustained expression or reaction of reprogramming
factors to prevent proper differentiation of iPSCs. Even
for future clinical applications, it would be necessary to
reprogram patient cells by using nonintegrating vectors
[31,36]. A number of studies have described successful
derivation of iPSCs by using adenoviral vectors, episo-
mal vectors, or the introduction of reprogramming pro-
teins, synthetic modified mRNA [37-40], but a vector-
free protocol is usually limited by the low efficiency of
iPSCs derivation. Given the rapid pace of the field,
further optimization of a highly efficient and vector-free
method of generation of iPSCs will facilitate the clinical
translation of this technology.
The iPSC technology allows the generation of disease-
and patient-specific iPSCs and offers a new cell model
for human disease-mechanism studies without ethical
controversies, as well as transplantation medicines
Figure 4 The induced pluripotent stem cells (iPSCs-DSs) have a methylation status similar to that of hESCs. The methylation status of
the endogenous OCT4 promoter in iPSCs-DS and parental human dermal fibroblasts was analyzed with bisulfite sequencing. Open circles
indicate unmethylated CpGs, and solid circles indicate methylated CpGs.
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Figure 5 The induced pluripotent stem cells (iPSCs-DSs) maintain pluripotency in vitro and in vivo. (A) Embryoid bodies (EBs) were
formed by the iPSCs-DS and semiquantitative reverse transcription polymerase chain reaction (RT-PCR) analyses of lineage markers that represent
the three germ layers. (B) Immunostaining showing expression of the three lineages markers Tuj1 (ectoderm), cTnT (mesoderm), and a-
fetoprotein (endoderm) in DS-iPSC clones from three independent iPSC derivations subjected to EBs differentiation. (C) Teratomas were collected
and stained with hematoxylin and eosin. The tissues originating from the three embryonic germ layers were present in the teratomas. Scale bars,
100 μm.
Figure 6 The induced pluripotent stem cells (iPSCs-DSs) maintain the same karyotypes as the parental human dermal fibroblasts
under G-band analysis. (A) DS/translocation-iPSC1 at passage 15. (B) DS/trisomy 21-iPSC2 at passage 12. (C) DS/trisomy 21-iPSC4 at passage 12.
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without immune rejection. With the technology, one
group created a human Marfan syndrome “model” to
prove the hypothesis that fibrillin-1 mutations result in
the disease phenotypes [41]. The hypothesis that the DS
gene is dosage dependent predicts that a region critical
for specific phenotypes contains a dosage-sensitive gene
or genes [1], of which a dosage imbalance results in the
formation of different phenotypes. The establishment of
different types of iPSC-DSs can be used to test this
hypothesis.
DS is the major cause of congenital heart disease and
the most frequent genetic cause of mental retardation. It
is also associated with increased risks of leukemia and
immune system defects. In a future study, the iPSC-DS
“model” can be used to differentiate cardiomyocytes,
neuron cells, and lymphocytes for transplantation to
improve the phenotypes of patients. For example, ventri-
cular septal defect is a common congenital heart disor-
der. In future clinical applications, it may be possible to
use functional cardiac tissue directly differentiated from
autologous iPSC in three-dimensional scaffold to repair
the defect [42]. In addition, the study of the differences
of cell behavior between the iPSCs-DS, iPSCs derived
from normal patients, and iPSCs-DS from different kar-
yotypes would be helpful to understand the disease
mechanism and the development of personalized
therapy.
Conclusions
Human dermal fibroblasts from patients with DS of var-
ious karyotypes were successfully reprogrammed into
iPSCs. All the iPSC-DS retained the abilities of self-
renewal and pluripotent potentials in vitro and in vivo.
DS-derived iPSCs offer the possibility for DS cell model-
ing, optimal patient care, drug discovery, and eventually,
autologous cell-replacement therapies.
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